COMMUNIQUÉS West-GlobeNewswire

Ibogaine By David Dardashti Launches New Software for Treatment Dose
07/05/2024
Optimizing Precision and Efficiency with Innovative Software MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti is proud to announce the launch of their new treatment dose software, designed to optimize [...]
Syntekabio to Showcase Biologics Discovery Platform at PEGS Boston
07/05/2024
Company offering discovery services for neoantigens with Neo-ARS and for full antibodies with Ab-ARS NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug [...]
Successful FDA Inspection at Dipharma Facility in Kalamazoo, MI, USA
07/05/2024
The Company expands its range of CGMP services to include small-scale commercial APIs MILAN, Italy, May 07, 2024 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a global Contract Development and Manufacturing [...]
Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development
07/05/2024
First-of-its-kind custom configurator – available today – gives scientists access to high quality, customizable buffers in small volumes for use in early-stage experiments, all with exceptionally short turnaround times [...]
FibroBiologics to Present at the BIO International Convention 2024
07/05/2024
HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of [...]
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
07/05/2024
- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limited Number of [...]
Medigene to Present at Upcoming Conferences
07/05/2024
Planegg/Martinsried, May 7, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]
Visory Health's New Prescription Habits Report Reveals Medication Affordability Challenges Among Millennials, the Sandwich Generation and Beyond
07/05/2024
As drug prices rise across America, millennials, the sandwich generation and older adults are turning to alternatives to afford prescriptions and other necessary bills ESTERO, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- [...]
Clinical Study Highlights Improvements to Gut Microbiome and Autism Spectrum Disorder Symptoms with Use of Custom Probiotics
07/05/2024
62% of Participants Reported Improvement in Overall Autism-related Symptoms and Gastrointestinal Discomfort SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Researchers with Sun Genomics and Arizona State University (ASU) [...]
HealthEquity Sets Date to Announce First Quarter Results
07/05/2024
Presentation at Conferences DRAPER, Utah, May 07, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today [...]
SI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical Procedures
07/05/2024
SANTA CLARA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the [...]
ALX Oncology Appoints Allison Dillon as Chief Business Officer
07/05/2024
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune [...]
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
07/05/2024
SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align [...]
Inmagene Announces Completion of Enrollment in Phase 2a Trial of IMG-007, a Nondepleting and Half-life Extended Anti-OX40 Monoclonal Antibody, in Patients with Alopecia Areata
07/05/2024
IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), is being evaluated in adult patients with alopecia areata (AA) and atopic dermatitis (AD). The enrollment of the Phase 2a study in AA [...]
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease
07/05/2024
Advances plan to launch T2Lyme Panel for detection of early Lyme disease Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. [...]
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
07/05/2024
Information relating to the holding of the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting BOULOGNE-BILLANCOURT, FRANCE, 7 [...]
IPSEN SA. - Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 28 mai 2024
07/05/2024
Informations concernant la tenue de l’Assemblée Générale Mixte du 28 mai 2024 d’Ipsen S.A. Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée BOULOGNE-BILLANCOURT, FRANCE, 7 mai [...]
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa
07/05/2024
Cannabix is developing alcohol and marijuana breathalyzer devices to give law enforcement and employers a tool to enhance public safety VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies [...]
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
07/05/2024
- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase 1b trial of INZ-701 [...]

Pages